Real World Data Archives

Publication

INTERCEPT-AD：一项针对阿尔茨海默病所致轻度认知障碍或轻度痴呆患者的静脉注射 Sabirnetug 的 I 期研究

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

Danielle Pillsbury2025 年 1 月 8 日

Video

Piet van der Graaf 谈人工智能和人工智能辅助药物研发方法

At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…

Danielle Pillsbury2024 年 12 月 10 日

Brochure

具有影响力的真实世界证据解决方案

Simona Colucci2024 年 10 月 9 日

Blog

Using Real World Data in Clinical Trial Submissions

We explore challenges & best practice recommendations to help you implement submission standards when using…

Certara2024 年 6 月 17 日

Case Study

Using Real World Evidence to Inform Treatment Guidelines

Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…

Danielle Pillsbury2023 年 4 月 5 日

White Paper

Using Real-world Evidence to Advance Market Access for New Therapeutics

Jim Gallagher2021 年 9 月 29 日

On-Demand Webinar

罕见病管理的“可怕”未来

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…

Jim Gallagher2021 年 9 月 23 日

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

Jim Gallagher2021 年 6 月 11 日

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

Jim Gallagher2021 年 6 月 11 日

On-Demand Webinar

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

Jim Gallagher2021 年 5 月 26 日

Real World Data

INTERCEPT-AD：一项针对阿尔茨海默病所致轻度认知障碍或轻度痴呆患者的静脉注射 Sabirnetug 的 I 期研究

Piet van der Graaf 谈人工智能和人工智能辅助药物研发方法

具有影响力的真实世界证据解决方案

Using Real World Data in Clinical Trial Submissions

Using Real World Evidence to Inform Treatment Guidelines

Using Real-world Evidence to Advance Market Access for New Therapeutics

罕见病管理的“可怕”未来

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

Stakeholder perspectives: current and potential benefits

订阅时事通讯

快捷链接

解决方案

联系我们